GlaxoSmithKline PLC

Board and Committee changes

RNS Number : 5792Z
GlaxoSmithKline PLC
27 May 2016
 

 

GlaxoSmithKline plc (the "Company")

Board and Committee changes

 

The Company announces that Dr Vivienne Cox, CBE, has been appointed to the Board of the Company as a Non-Executive Director with effect from 1 July 2016.  She has been appointed a member of the Corporate Responsibility Committee, also effective from 1 July 2016.

 

Commenting on the appointment, Philip Hampton, Chairman of GlaxoSmithKline plc, said "I am delighted Vivienne is joining the Board. She brings with her many years of international business experience in complex global manufacturing organisations with challenging technologies. My colleagues and I very much look forward to welcoming her to GSK."

Dr Cox has wide experience of business gained in the energy, natural resources and publishing sectors. She worked for BP plc for 28 years, in Britain and Continental Europe, in posts including executive vice president and chief executive of BP's gas, power and renewables business and its alternative energy unit.

Dr Cox is currently Senior Independent Director of Pearson plc, the Chairman of its Reputation & Responsibility Committee, and a member of its Audit, Nomination and Remuneration Committees. She is Non-Executive Director of Stena International and Chairman of the Supervisory Board of Vallourec, a supplier to the energy industry. She is also Lead Independent Director at the UK Government's Department for International Development. She was previously a Non-Executive Director of BG Group plc and Rio Tinto plc.

Dr Cox was appointed Commander of the Order of the British Empire in the 2016 New Year Honours for services to the UK Economy and Sustainability.

 

V A Whyte

Company Secretary

 

27 May 2016

 



 

Notes

 

1.   As Non-Executive Director of GSK, Dr Cox will receive standard annual fees of £85,000 per annum.  To enhance the link between Non-Executive Directors and shareholders, at least 25% of her fees will be paid in the form of Ordinary Shares and allocated to a share account, and she will be able to invest part or all of the balance of her fees into the same share account.

 

2.   The Board has determined that Dr Cox will be an independent Non-Executive Director, in accordance with the UK Corporate Governance Code. In addition, the Company confirms that there are no further disclosures to be made in connection with Dr Cox's appointment in accordance with Listing Rule 9.6.13R.

 

3.   With effect from 1 July 2016, the composition of the Board of GSK will be as follows:

 

Sir Philip Hampton        

Non-Executive Chairman

Sir Andrew Witty

Chief Executive Officer

Mr Simon Dingemans

Chief Financial Officer

Dr Moncef Slaoui

Chairman, Global Vaccines

Professor Sir Roy Anderson

Independent Non-Executive Director

Mr Vindi Banga

Senior Independent Non-Executive Director

Ms Stacey Cartwright

Dr Vivienne Cox

Independent Non-Executive Director

Independent Non-Executive Director

Ms Lynn Elsenhans

Dr Jesse Goodman

Independent Non-Executive Director

Independent Non-Executive Director

Ms Judy Lewent

Independent Non-Executive Director

Mr Urs Rohner

Independent Non-Executive Director

 

 



 

GSK - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com.

 

GSK enquiries:




UK Media enquiries:

David Mawdsley

+44 (0) 20 8047 5502

(London)


Simon Steel

+44 (0) 20 8047 5502

(London)





US Media enquiries:

Sarah Alspach

+1 202 715 1048

(Washington, DC)


Sarah Spencer

+1 215 751 3335

(Philadelphia)


Jenni Ligday

+1 202 715 1049

(Washington, DC)





Analyst/Investor enquiries:

Ziba Shamsi

+44 (0) 20 8047 5543

(London)


Tom Curry

+ 1 215 751 5419

(Philadelphia)


Gary Davies

+44 (0) 20 8047 5503

(London)


James Dodwell

+44 (0) 20 8047 2406

(London)


Jeff McLaughlin

+1 215 751 7002

(Philadelphia)

 

Cautionary statement regarding forward-looking statements

GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D 'Risk factors' in the company's Annual Report on Form 20-F for 2015.

 

Registered in England & Wales:

No. 3888792


Registered Office:

980 Great West Road

Brentford, Middlesex

TW8 9GS

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOABXGDUDUDBGLR